Synapse-tuned CARs enhance immune cell anti-tumor activity
Synapse-tuned CARs enhance immune cell anti-tumor activity
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Chimeric antigen receptor (CAR) technologies have been clinically implemented for the treatment of hematological malignancies; however, solid tumors remain resilient to CAR therapeutics. Natural killer (NK) cells may provide an optimal class of immune cells for CAR-based approaches due to their inherent anti-tumor functionality. In this study, we s...
Alternative Titles
Full title
Synapse-tuned CARs enhance immune cell anti-tumor activity
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10394118
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10394118
Other Identifiers
ISSN
1087-0156,1546-1696
E-ISSN
1546-1696
DOI
10.1038/s41587-022-01650-2
